Session » Pediatric Rheumatology – Clinical and Therapeutic Aspects Poster III: Juvenile Arthritis

Date: Tuesday, November 7, 2017

Time: 9:00AM-11:00AM

Meeting: 2017 ACR/ARHP Annual Meeting

9:00AM-11:00AM: Abstract Number: 2283

Adalimumab Therapy in Juvenile Idiopathic Arthritis: Addition of Lidocaine for Prevention of Injection Site Pain or Not? That Is the Question. a Comparison Study

9:00AM-11:00AM: Abstract Number: 2273

An Open-Label Extension Study to Assess the Long-Term Safety of Etanercept in Pediatric Patients with Extended Oligo, Enthesitis Related, and Psoriatic Juvenile Idiopathic Arthritis: 6-Year Data from the Clipper Studies

9:00AM-11:00AM: Abstract Number: 2301

Assessing the Utility and Impact of Musculoskeletal Ultrasound in a Large Pediatric Rheumatology Clinic

9:00AM-11:00AM: Abstract Number: 2316

Barriers at School for Children with Juvenile Idiopathic Arthritis (JIA) – a Patient Reported Outcome

9:00AM-11:00AM: Abstract Number: 2278

Biologic Switching Among JIA Patients: A Cohort Study in the Childhood Arthritis and Rheumatology Research Alliance Registry

9:00AM-11:00AM: Abstract Number: 2287

Biosimilar Use in Children and Young People with Juvenile Idiopathic Arthritis in a Real-World Setting in the United Kingdom

9:00AM-11:00AM: Abstract Number: 2293

Can We Predict Achievement of Clinically Inactive Disease and Sustained Remission in Children with Juvenile Idiopathic Arthritis?

9:00AM-11:00AM: Abstract Number: 2299

Clinical Features and Characteristics of Juvenile Idiopathic Arthritis-Associated Uveitis in Japan：the First Report from the Pediatric Rheumatology Association of Japan (PRAJ)

9:00AM-11:00AM: Abstract Number: 2290

Comparing Effectiveness of Early Initiation of Biologic Treatment for Newly Diagnosed Juvenile Idiopathic Arthritis Using a Novel Statistics Causal Inference Method Applied to Observational Data

9:00AM-11:00AM: Abstract Number: 2306

Demographic and Clinical Characteristics of Hispanic Children with Juvenile Idiopathic Arthritis: An International, Multicenter Cross-Sectional Study

9:00AM-11:00AM: Abstract Number: 2286

Determinants of Anti-Tumor Necrosis Factor Drug Use in Juvenile Spondyloarthropathy and Impact on Clinical Disease Outcomes

9:00AM-11:00AM: Abstract Number: 2279

Dynamics of Concomitant Therapy in Children with Juvenile Idiopathic Arthritis Treated with Etanercept

9:00AM-11:00AM: Abstract Number: 2292

Effectiveness of Common Treatment Strategies for Juvenile Arthritis in Usual Practice: Results from the Research in Arthritis in Canadian Children Emphasizing Outcomes Cohort

9:00AM-11:00AM: Abstract Number: 2280

Effectiveness of Switching to Adalimumab As the Second- and Third-Line Biological Drug in Patients with Juvenile Idiopathic Arthritis

9:00AM-11:00AM: Abstract Number: 2305

Efficacy of Function-Based Exercise Program on Functional Ability, Pain and Quality of Life in Children with Juvenile Idiopathic Arthritis

9:00AM-11:00AM: Abstract Number: 2276

Etanercept (Enbrel®) Treatment Retention in the Sub-Population of Pediatric Patients from a Retrospective Cohort Study Using Canadian Claims-Level Data

9:00AM-11:00AM: Abstract Number: 2298

Etanercept, Adalimumab and Methotexate Utilization By Juvenile Idopathic Arthritis Patients and the Occurrence of Uveitis

9:00AM-11:00AM: Abstract Number: 2275

Factors Related to Sustained Discontinuation of Medications for Well-Controlled JIA in the Childhood Arthritis & Rheumatology Research Alliance Registry

9:00AM-11:00AM: Abstract Number: 2307

Frequency of Comorbidities in Patients with Juvenile Ideopathic Arthritis – Results of an Observational Cohort Study

9:00AM-11:00AM: Abstract Number: 2297

Golimumab Versus Tocilizumab in Uveitis Related to Refractory Juvenile Idiopathic Arthritis. National Multicenter Study of 33 Patients

9:00AM-11:00AM: Abstract Number: 2270

Identification of Optimal Subcutaneous Doses of Tocilizumab in Children with Polyarticular-Course Juvenile Idiopathic Arthritis

9:00AM-11:00AM: Abstract Number: 2310

Increased Risk of Extreme Obesity in Adults with History of Childhood Arthritis

9:00AM-11:00AM: Abstract Number: 2289

Individualized Prediction of Early Remission on Medication in Juvenile Idiopathic Arthritis

9:00AM-11:00AM: Abstract Number: 2296

Infliximab Use in JIA and Uveitis: Does Methotrexate Help or Hinder?

9:00AM-11:00AM: Abstract Number: 2304

Joint Injection Practices in Pediatric Rheumatology – Preliminary Data from an Ongoing Web Based Survey

9:00AM-11:00AM: Abstract Number: 2317

Knowledge Translation in Juvenile Idiopathic Arthritis in Canada: A Focus on Parents of Children with JIA

9:00AM-11:00AM: Abstract Number: 2272

Long-Term Effectiveness and Safety of Abatacept in Juvenile Idiopathic Arthritis: Ongoing Results from the Abatacept in JIA Registry

9:00AM-11:00AM: Abstract Number: 2295

Methotrexate As First Line Therapy in Juvenile Idiopathic Arthritis-Associated Uveitis: Myth or Reality

9:00AM-11:00AM: Abstract Number: 2314

Monoarticular Juvenile Idiopathic Arthritis: A Unique Entity?

9:00AM-11:00AM: Abstract Number: 2281

Patterns of Medication Use in Non-Systemic Polyarthritis: Data from the Childhood Arthritis and Rheumatology Research Alliance Patient Registry

9:00AM-11:00AM: Abstract Number: 2300

Predictive Value of Magnetic Resonance Imaging in Patients with Juvenile Idiopathic Arthritis in Clinical Remission

9:00AM-11:00AM: Abstract Number: 2312

Prevalence of Serum 14-3-3η (eta) in Juvenile Idiopathic Arthritis

9:00AM-11:00AM: Abstract Number: 2313

Procalcitonin Differentiates Infection from Active Disease in Patients with Juvenile Idiopathic Arthritis

9:00AM-11:00AM: Abstract Number: 2311

Prospective Validation of the Juvenile Spondyloarthritis Disease Activity Index and Its Comparison with Adult Spondyloarthritis Disease Activity Scores

9:00AM-11:00AM: Abstract Number: 2309

Risk Factors for Arthritis and the Development of Comorbid Cardiovascular and Metabolic Disease in Children with Psoriasis

9:00AM-11:00AM: Abstract Number: 2274

Risk of Serious Events, Serious Infections, Uveitis, Crohn’s Disease, Colitis and Malignancies in Patients with Juvenile Idiopathic Arthritis on Continuous Treatment with Etanercept over Time: A Report from a Biologics Registry

9:00AM-11:00AM: Abstract Number: 2271

Safety of Adalimumab±Methotrexate for the Treatment of Polyarticular Juvenile Idiopathic Arthritis (pJIA)

9:00AM-11:00AM: Abstract Number: 2277

Safety of Biologic Therapies for the Treatment of Juvenile Idiopathic Arthritis: Results from the Spanish Registry of Adverse Events with Biologic Therapies (BIOBADASER)

9:00AM-11:00AM: Abstract Number: 2303

Six Minute Walk Test in Childreh with Juvenile Idiopathic Arthritis: Normative Values, Prediction Equation, and Comparison to Healthy Children

9:00AM-11:00AM: Abstract Number: 2288

Successful Treatment of Methotrexate Intolerance in Juvenile Idiopathic Arthritis Using Eye Movement Desensitization and Reprocessing (EMDR)

9:00AM-11:00AM: Abstract Number: 2315

Symptoms of Depression and Anxiety in Children with JIA: Relation to Other Domains of Health Related Quality of Life

9:00AM-11:00AM: Abstract Number: 2282

The Childhood Arthritis and Rheumatology Research Alliance Start Time Optimization of Biologic Therapy in Polyarticular JIA Study: Interim Report of Baseline Patient Characteristics and Treatment Choices

9:00AM-11:00AM: Abstract Number: 2302

The Impact of JIA on Physician and Patient-Reported Outcomes over the First Five Years Following Diagnosis

9:00AM-11:00AM: Abstract Number: 2308

The Prevalence of Comorbidities in Pediatric Psoriasis and Juvenile Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 2291

Three Treatment Strategies in Recent Onset DMARD Naive Juvenile Idiopathic Arthritis: First Results of Clinical Outcome after 24 Months

9:00AM-11:00AM: Abstract Number: 2285

Treatment of Adult Juvenile Idiopathic Arthritis Patients with Biologic Agents. Data from the National Registry

9:00AM-11:00AM: Abstract Number: 2284

Use of Biological Therapies in Adult Patients Diagnosed with Juvenile Idiopathic Arthritis: Results from the Spanish Registry of Adverse Events with Biologic Therapies (BIOBADASER)

9:00AM-11:00AM: Abstract Number: 2294

Utilizing the Pediatric Rheumatology Care and Outcomes Improvement Network to Assess Practice Pattern Variation in Juvenile Idiopathic Arthritis

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].